PSY19 - Public Health Expenditure In Patients With Non-Hodgkin's Lymphoma In Mexican Institutions

Abstract

Non-Hodgkin lymphoma (NHL) represents about 54% of all types of blood cancer and it includes all types of lymphoma. The 5-year prevalence of the disease in Mexico is approximately 8,700 patients/year, and 2,558 people die each year from the disease. Evaluate the health expenditure of Mexican public institutions on patients with NHL in order to understand the investment to these patients. Hematologists were interviewed from public institutions, to understand current treatment regimens. Based on the current treatment, a descriptive analysis of the purchase of these drugs in three public health institutions (IMSS, ISSSTE and PEMEX) in the period from 2015 to 2017 was performed. The number of patients with NHL by institution was calculated and the average investment per patient is reported. From the three Institutions IMSS had the greatest expenditure in the purchase of NHL medicines, with 128% more than ISSSTE and 2,655% more than PEMEX during the three years. Similarly, it was found that IMSS has the largest population with NHL being 371% higher than ISSSTE and 7,689% more than PEMEX. However, when evaluating the average investment per patient, PEMEX has the highest investment per patient (˜$6,000USD/patient, avg.), being 175% higher than IMSS and 6% more than ISSSTE. The Institution with greatest expenditure for NHL patients in Mexico was IMSS, however, the investment per patient is less compared to the other Institutions, largely due to the disproportion between budget and affiliated population. The population with NHL throughout time represents important growth rates, in contrast the annual expenditure by the institutions diminished approximately 20% from the 2015 expenditure, therefore less budget is available for purchasing novel agents. The investment in these chronic diseases should be increased consistent with population growth, therefore it’s important to evaluate the creation of specific budgets for innovative drugs under a correct profiling of patients.